Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotrectinib in Solid Tumors Harboring NTRK Fusion
NCT02576431Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2015
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 25
01
Overview
Phase 2, open-label trial of larotrectinib in solid tumor (11 arms), sponsored by Bayer. Primary endpoint: Objective Response Rate up to 120 months. Started Sep 2015; status: completed.
02
Drugs
larotrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02576431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576431.